



# 1,1,1-TRICHLOROETHANE AND FOUR OTHER INDUSTRIAL CHEMICALS

VOLUME 130

This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met remotely, 7–22 October 2021

LYON, FRANCE - 2022

IARC MONOGRAPHS  
ON THE IDENTIFICATION  
OF CARCINOGENIC HAZARDS  
TO HUMANS

# CONTENTS

---

<b>NOTE TO THE READER</b> .....	<b>1</b>
<b>LIST OF PARTICIPANTS</b> .....	<b>3</b>
<b>PREAMBLE</b> .....	<b>7</b>
<b>A. GENERAL PRINCIPLES AND PROCEDURES</b> .....	<b>7</b>
1. Background.....	7
2. Objective and scope.....	8
3. Selection of agents for review .....	9
4. The Working Group and other meeting participants.....	9
5. Working procedures.....	11
6. Overview of the scientific review and evaluation process .....	12
7. Responsibilities of the Working Group.....	14
<b>B. SCIENTIFIC REVIEW AND EVALUATION</b> .....	<b>15</b>
1. Exposure characterization .....	15
2. Studies of cancer in humans.....	18
3. Studies of cancer in experimental animals.....	23
4. Mechanistic evidence .....	26
5. Summary of data reported.....	29
6. Evaluation and rationale.....	30
References.....	35
<b>GENERAL REMARKS</b> .....	<b>39</b>
<b>1,1,1-TRICHLOROETHANE</b> .....	<b>43</b>
1. Exposure Characterization .....	43
1.1 Identification of the agent .....	43
1.2 Production and use.....	44
1.3 Detection and quantification.....	47
1.4 Occurrence and exposure.....	51
1.5 Regulations and guidelines .....	57
1.6 Quality of exposure assessment in key epidemiological studies of cancer and mechanistic studies in humans .....	58

2. Cancer in Humans	66
2.1 Cancers of the haematopoietic and lymphoid tissues	68
2.2 Cancers of the brain and nervous system	84
2.3 Cancer of the breast	95
2.4 Cancers of the kidney and urinary bladder	105
2.5 Cancers of the digestive, respiratory, or genital tract, and other solid cancers	119
2.6 Evidence synthesis for cancer in humans	136
3. Cancer in Experimental Animals	143
3.1 Mouse	143
3.2 Rat	153
3.3 Evidence synthesis for cancer in experimental animals	155
4. Mechanistic Evidence	156
4.1 Absorption, distribution, metabolism, and excretion	156
4.2 Evidence relevant to key characteristics of carcinogens	165
4.3 Other relevant evidence	183
5. Summary of Data Reported	184
5.1 Exposure characterization	184
5.2 Cancer in humans	185
5.3 Cancer in experimental animals	185
5.4 Mechanistic evidence	186
6. Evaluation and Rationale	187
6.1 Cancer in humans	187
6.2 Cancer in experimental animals	187
6.3 Mechanistic evidence	187
6.4 Overall evaluation	187
6.5 Rationale	187
References	188
<b>1,2-DIPHENYLHYDRAZINE</b>	<b>203</b>
1. Exposure Characterization	203
1.1 Identification of the agent	203
1.2 Production and use	204
1.3 Detection and quantification	205
1.4 Occurrence and exposure	205
1.5 Regulations and guidelines	206
2. Cancer in Humans	207
3. Cancer in Experimental Animals	207
3.1 Mouse	207
3.2 Rat	213
3.3 Evidence synthesis for cancer in experimental animals	216
4. Mechanistic Evidence	217
4.1 Absorption, distribution, metabolism, and excretion	217
4.2 Evidence relevant to key characteristics of carcinogens	218
5. Summary of Data Reported	224
5.1 Exposure characterization	224
5.2 Cancer in humans	224

---

5.3 Cancer in experimental animals.....	224
5.4 Mechanistic evidence .....	224
6. Evaluation and Rationale.....	225
6.1 Cancer in humans.....	225
6.2 Cancer in experimental animals.....	225
6.3 Mechanistic evidence .....	225
6.4 Overall evaluation .....	225
6.5 Rationale .....	225
References.....	225
<b>DIPHENYLAMINE .....</b>	<b>229</b>
1. Exposure Characterization .....	229
1.1 Identification of the agent .....	229
1.2 Production and use.....	230
1.3 Detection and quantification.....	231
1.4 Occurrence and exposure.....	233
1.5 Regulations and guidelines .....	242
2. Cancer in Humans .....	244
3. Cancer in Experimental Animals .....	244
3.1 Mouse.....	244
3.2 Rat .....	249
3.3 Dog .....	251
3.4 Evidence synthesis for cancer in experimental animals .....	251
4. Mechanistic Evidence.....	252
4.1 Absorption, distribution, metabolism, and excretion .....	252
4.2 Evidence relevant to key characteristics of carcinogens.....	256
5. Summary of Data Reported .....	265
5.1 Exposure characterization .....	265
5.2 Cancer in humans .....	265
5.3 Cancer in experimental animals.....	266
5.4 Mechanistic evidence .....	266
6. Evaluation and Rationale.....	267
6.1 Cancer in humans.....	267
6.2 Cancer in experimental animals.....	267
6.3 Mechanistic evidence .....	267
6.4 Overall evaluation .....	267
6.5 Rationale .....	267
References.....	267
<b>N-METHYLOLACRYLAMIDE.....</b>	<b>273</b>
1. Exposure Characterization .....	273
1.1 Identification of the agent .....	273
1.2 Production and use.....	274
1.3 Detection and quantification.....	275
1.4 Occurrence and exposure.....	275
1.5 Regulations and guidelines .....	278

2. Cancer in Humans .....	278
3. Cancer in Experimental Animals .....	278
3.1 Mouse .....	286
3.2 Rat .....	289
3.3 Evidence synthesis for cancer in experimental animals .....	289
4. Mechanistic Evidence.....	290
4.1 Absorption, distribution, metabolism, and excretion .....	290
4.2 Evidence relevant to key characteristics of carcinogens.....	291
4.3 Other relevant evidence .....	299
5. Summary of Data Reported .....	299
5.1 Exposure characterization .....	299
5.2 Cancer in humans.....	300
5.3 Cancer in experimental animals.....	300
5.4 Mechanistic evidence .....	300
6. Evaluation and Rationale.....	301
6.1 Cancer in humans.....	301
6.2 Cancer in experimental animals.....	301
6.3 Mechanistic evidence .....	301
6.4 Overall evaluation .....	301
6.5 Rationale .....	301
References.....	301

<b>ISOPHORONE.....</b>	<b>307</b>
1. Exposure Characterization .....	307
1.1 Identification of the agent .....	307
1.2 Production and use.....	308
1.3 Detection and quantification.....	308
1.4 Occurrence and exposure.....	313
1.5 Regulations and guidelines .....	328
1.6 Quality of exposure assessment in key epidemiological studies of cancer .....	330
2. Cancer in Humans .....	331
2.1 Cohort study.....	331
2.2 Evidence synthesis for cancer in humans.....	331
3. Cancer in Experimental Animals .....	334
3.1 Mouse .....	334
3.2 Rat .....	338
3.3 Evidence synthesis for cancer in experimental animals .....	339
4. Mechanistic Evidence.....	340
4.1 Absorption, distribution, metabolism, and excretion.....	340
4.2 Evidence relevant to key characteristics of carcinogens.....	342
4.3 Other relevant evidence .....	348
5. Summary of Data Reported .....	349
5.1 Exposure characterization .....	349
5.2 Cancer in humans.....	350
5.3 Cancer in experimental animals.....	350
5.4 Mechanistic evidence .....	350

6. Evaluation and Rationale. ....	351
6.1 Cancer in humans. ....	351
6.2 Cancer in experimental animals. ....	351
6.3 Mechanistic evidence. ....	351
6.4 Overall evaluation. ....	351
6.5 Rationale. ....	351
References. ....	351
<b>LIST OF ABBREVIATIONS. ....</b>	<b>359</b>
<b>ANNEX 1. Supplementary material for 1,1,1-trichloroethane,     Section 1, Exposure Characterization. ....</b>	<b>361</b>
<b>ANNEX 2. Supplementary material for Section 4, Mechanistic Evidence. ....</b>	<b>363</b>
<b>ANNEX 3. Supplementary material for isophorone, Section 1, Exposure Characterization. ....</b>	<b>365</b>
<b>SUMMARY OF FINAL EVALUATIONS. ....</b>	<b>367</b>

